繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 呼吸系统病 >> DuoResp Spiromax(慢性阻塞性肺病和哮喘新的干粉吸入剂)

DuoResp Spiromax(慢性阻塞性肺病和哮喘新的干粉吸入剂)

2015-01-10 17:23:11  作者:新特药房  来源:互联网  浏览次数:223  文字大小:【】【】【
简介:2014年7月13日,梯瓦药物DuoResp Spiromax获欧盟委员会(EC)批准,用于适合糖皮质激素和长效β2-肾上腺素受体激动剂组合疗法的慢性阻塞性肺病(COPD)和哮喘(asthma)患者的治疗。DuoResp Spiromax(budesonide & fo ...

2014年7月13日,梯瓦药物DuoResp Spiromax获欧盟委员会(EC)批准,用于适合糖皮质激素和长效β2-肾上腺素受体激动剂组合疗法的慢性阻塞性肺病(COPD)和哮喘(asthma)患者的治疗。
DuoResp Spiromax(budesonide & formoterol fumarate dihydrate,布地奈德 福莫特罗富马酸盐二水合物)是一种新的多剂量干粉吸入剂,由布地奈德(budesonide)和福莫特罗(formoterol)组成。布地奈德是一种吸入性皮质类固醇(ICS),用于治疗哮喘患者和COPD患者潜在的炎症;福莫特罗是一种速效和长效β2激动剂(LABA),用于缓解哮喘患者和COPD患者的支气管收缩(bronchoconstriction )。Spiromax吸入器采用独特的呼吸驱动技术,能够递送一致剂量的药物。
DuoResp Spiromax的开发,旨在改善药物的易用性,并递送一致剂量的药物。由于吸入器技术的落后,许多哮喘和COPD患者存在治疗不足(under-treated)的情况,这导致了额外的就诊次数以及需要紧急护理等形式的不必要负担。
DuoResp Spiromax将进入吸入性皮质类固醇/长效β2激动剂(ICS/LABA)固定剂量组合吸入剂细分市场,在全球范围内,ICS/LABA药物销售额达139亿美元,欧洲市场销售额达44亿美元。


DuoResp Spiromax (formoterol/budesonide) has been launched for use in adults with asthma or chronic obstructive pulmonary disease (COPD), where use of an inhaled corticosteroid and a long-acting beta2 agonist is appropriate.
The breath-actuated dry powder inhaler is available in two strengths:
•160/4.5 (formoterol fumarate dihydrate 6 microgram, budesonide 200 microgram per dose) - equivalent to Symbicort 200/6 Turbohaler
•320/9 (formoterol fumarate dihydrate 12 microgram, budesonide 400 microgram per dose) - equivalent to Symbicort 400/12 Turbohaler.
In asthma, the 160/4.5 inhaler may be used both as regular maintenance treatment and as needed in response to symptoms. The 320/9 inhaler must be used with a separate reliever.
In COPD, both inhalers are indicated for symptomatic treatment in patients with a forced expiratory volume in one second (FEV1) <50% predicted normal and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
The Spiromax device has a design similar to that of pressurised metered-dose inhalers. There are three steps to using the inhaler: open, breathe and close. No priming is required. Dose confirmation is provided by a 'click' sound, lactose taste and a dose indicator.

Name DuoResp Spiromax
Agency product number EMEA/H/C/002348
Active substance

budesonide / formoterol fumarate dihydrate

International non-proprietary name (INN) or common name

budesonide / formoterol

Therapeutic area AsthmaPulmonary Disease, Chronic Obstructive
Anatomical therapeutic chemical (ATC) code R03AK07

Publication details

Publication details for DuoResp Spiromax
Marketing-authorisation holder

Teva Pharma B.V.

Revision 0
Date of issue of marketing authorisation valid throughout the European Union 28/04/2014

Contact address:

Teva Pharma B.V.
Computerweg 10 
3542DR Utrecht
The Netherlands

Name Language First published Last updated
DuoResp Spiromax : EPAR - Public assessment report (English only) 20/05/2014  
CHMP summary of positive opinion for DuoResp Spiromax (English only) 21/02/2014

责任编辑:admin


相关文章
Viread(Tenofovir Disoproxil Fumarate Tablets/Powder)
Flutiform(复方丙酸氟替卡松/富马酸福莫特罗吸入剂)
Flutiform Aerosol(复方丙酸氟替卡松/富马酸福莫特罗吸入剂
TECFIDERA(dimethyl fumarate delayed-release capsules)
UCERIS rectal foam(布地奈德直肠泡沫剂)
Uceris(Budesonide)布地奈德揿压式气雾剂
Fostair NEXThaler(丙酸倍氯米松无水/富马酸福莫特罗二水吸入粉)
Duaklir Genuair(复方阿地溴铵/富马酸福莫特罗吸入干粉剂)
Galfer FA(Ferrous fumarate, folic acid capsules) 富马酸亚铁叶酸胶囊
Vonoprazan fumarate(TAK-438) 富马酸沃诺拉赞片
 

最新文章

更多

· 妥布霉素吸入干粉|TOBI ...
· ORKAMBI(IVACAFTOR/LUMA...
· Ofev Capsules(Ninteda...
· Ofev(Nintedanib Capsules)
· FLUIMUCIL 10% (乙酰半胱...
· OLOPATADINE HYDROCHLOR...
· Tessalon Capsules(苯佐...
· OFEV(NINTEDANIB ESYLAT...
· 间质性肺炎新药Ofev已获...
· STIOLTO RESPIMAT(tiotr...

推荐文章

更多

· 妥布霉素吸入干粉|TOBI ...
· ORKAMBI(IVACAFTOR/LUMA...
· Ofev Capsules(Ninteda...
· Ofev(Nintedanib Capsules)
· FLUIMUCIL 10% (乙酰半胱...
· OLOPATADINE HYDROCHLOR...
· Tessalon Capsules(苯佐...
· OFEV(NINTEDANIB ESYLAT...
· 间质性肺炎新药Ofev已获...
· STIOLTO RESPIMAT(tiotr...

热点文章

更多

· Ofev Capsules(Ninteda...
· ORKAMBI(IVACAFTOR/LUMA...
· 妥布霉素吸入干粉|TOBI ...